– Achieves development milestones required to complete Series A financing – – Plans to file Phase 2 investigational new drug (IND) application by year end, with first patient dosing in Q1 2023 – Toronto, Canada, September 19, 2022 – Zucara Therapeutics Inc., (“Zucara” or the “Company”) a diabetes life sciences company developing the first once-daily […]